Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 15/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675098 | 1.00 | GHSR (0.66) | GHSR | |
| SCHEMBL28021776 | 1.00 | GHSR (0.66) | GHSR | |
| SCHEMBL9726172 | 1.00 | GHSR (0.66) | GHSR | |
| SCHEMBL29973265 | 0.95 | GHSR (0.60) | GHSR | |
| Examorelin SCHEMBL28022186 | 0.94 | GHSR (0.60) | GHSR | |
| Examorelin SCHEMBL29403103 | 0.94 | GHSR (0.60) | GHSR | |
| Examorelin SCHEMBL29805730 | 0.94 | GHSR (0.60) | GHSR | |
| Examorelin SCHEMBL26959 | 0.94 | GHSR (0.60) | GHSR | |
| Examorelin SCHEMBL6219689 | 0.93 | GHSR (0.59) | GHSR | |
| Examorelin SCHEMBL8580589 | 0.93 | GHSR (0.59) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628133-B2 | Uses of the peptide of sequence His-D-Trp-Ala-Trp-d-Phe-Lys-NH2 for reducing or delaying the appearance of cell senescence and signs of skin aging | ISP INVESTMENTS LLC (US) | 2023-04-18 | — | — | US | claimed |
| US-20250360156-A1 | SYNERGISTIC COMBINATION OF NAD+ AND THERAPEUTIC PEPTIDES DELIVERED VIA IONTOPHORESIS FOR ENHANCED AND PROLONGED REGENERATIVE EFFECTS | ANDREWS NICHOLAS JEROME (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240158438-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2024-05-16 | — | — | US | disclosed |
| EP-4321525-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | Chengdu Sintanovo Biotechnology Co., Ltd (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20230330187-A1 | USE OF GHRELIN OR GHRELIN VARIANT FOR INCREASING DOSE INTENSITY OF CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH CANCER | OXEIA BIOPHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | disclosed |
| US-11628133-B2 | Uses of the peptide of sequence His-D-Trp-Ala-Trp-d-Phe-Lys-NH2 for reducing or delaying the appearance of cell senescence and signs of skin aging | ISP INVESTMENTS LLC (US) | 2023-04-18 | — | — | US | disclosed |
| US-11628133-B2 | Uses of the peptide of sequence His-D-Trp-Ala-Trp-d-Phe-Lys-NH2 for reducing or delaying the appearance of cell senescence and signs of skin aging | ISP INVESTMENTS LLC (US) | 2023-04-18 | — | — | US | disclosed |
| EP-2981292-B1 | SUPRAMOLECULAR AGGREGATES COMPRISING A MALEIMIDO CORE | UFPEPTIDES S R L (IT) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022206587-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | 成都诺和晟泰生物科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| EP-3182992-A1 | METHODS OF TREATING MILD BRAIN INJURY | Oxeia Biopharmaceuticals Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2017075535-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016048488-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016028826-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20150265680-A1 | THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| EP-2913063-A1 | THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-5137874-A | For parenteral administration | AMERICAN CYANAMID CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0211267-B1 | CONTINUOUS RELEASE PEPTIDE COMPOSITIONS | AMERICAN CYANAMID COMPANY (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0211267-A2 | Continuous release peptide compositions | AMERICAN CYANAMID COMPANY (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158438-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | GHSR, GHRHR, GIPR | GHSR 1/4885 |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | HTT, SNCA, NLN | GHSR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.